[英文新闻]Spring Bank Pharma wins $3.9M NIH grant to fight Hep B

StephenW

Milford company Spring Bank Pharmaceuticals Inc. has landed a $3.9 million grant from the National Institutes of Health to further develop a drug candidate to treat Hepatitis B infections.

The five-year grant came from the NIH division, the National Institute of Allergy and Infectious Diseases, and becomes the fourth federal grant the company has taken in based on its platform technology, for a total of more than $12 million, officials said in a release.
http://www.masshightech.com/stories/2011/05/02/daily53-Spring-Bank-Pharma-wins-39M-NIH-grant-to-fight-Hep-B.html
Spring Bank is developing drug candidates under its Small Nucleic Acid Hybrid (SMNH) technology, and the candidate this newest grant is supporting is labeled SB 9200, which the company says can be taken orally.

Founded in 2002 as Spring Bank Technologies Inc., the company changed to its current name in the middle of 2010. The company has been working on a treatment for Hepatitis B at least as far back as 2003, when it licensed a compound called MBI-1313 from Canadian biotech Micrologix Biotech Inc. for up to $3.5 million in payments. At the same time, Spring Bank landed $2.6 million from the NIH to advance that compound.

Spring Bank was founded by CEO Douglas Jensen and chief scientific officer Radhakrishnan P. “Kris” Iyer.

StephenW

米尔福德公司斯普林班克制药公司已经找到了一份由美国国立卫生研究院拨款390万美元，以进一步开发候选药物治疗乙型肝炎病毒携带者。

五年批来自美国国立卫生研究院司，国家过敏与传染病，并成为第四个联邦赠款，该公司已在基于其平台技术为超过1200万美元计，，官员说，在一释放。

Spring Bank是根据其发展小核酸杂交（SMNH）技术的候选药物，并给予该候选人是支持这个最新的标记SB9200，该公司表示，可以采取口头。

成立于2002年的Spring Bank技术公司，改变了2010年中期到目前的公司名称。该公司一直在努力的治疗，至少可以追溯到2003年，当时它叫做授权来自加拿大生物技术公司MBI的生物技术Micrologix- 1313最多为350万美元付款，B型肝炎的化合物。同时，
Spring Bank
落在距国家卫生研究院的260万美元以推动该化合物。


Spring Bank
成立由首席执行官道格拉斯Jensen和首席科学官拉达克里希南体育“克里斯“艾耶。

StephenW

http://www.springbankpharm.com/
Spring Bank Pharmaceuticals is an IND-stage drug discovery company. Based on our proprietary platform technology, we are developing a pipeline of products representing a new class of pharmaceuticals we call small molecule nucleic acid hybrids “SMNH” with a wide range of applications and multi-billion dollar market potential.

These rationally designed molecules combine the target selectivity and specificity advantages of nucleic-acid-based therapeutics, like RNAi and antisense oligonucleotides, with the drug-like properties of classical pharmaceuticals, including oral delivery, good pharmacokinetics, low side effects and ease of manufacture.  Our most advanced product is SB 9200, a potential breakthrough drug for Hepatitis B and C with both direct antiviral and immune stimulatory activities, for which we plan to begin Phase I trials in 2011. Behind SB 9200 are drug discovery programs for COPD, other viral infections and cancer.

斯普林班克制药公司是一个实业阶段的药物研发公司。我们的专有技术平台的基础上，我们正在开发一种较新的药品类产品流水线，我们调用的应用程序和多亿美元的市场潜力大范围的小分子核酸杂交“SMNH“。

这些设计合理的目标分子结合核酸的选择性和酸的疗法如RNAi和反义寡核苷酸，特异性的优点，与传统药品，包括口服给药，良好的药代动力学，低副作用的药物，如性能，易于制造。我们最先进的产品是SB9200，一B和C型肝炎的潜在突破性的直接抗病毒和免疫刺激活动，我们计划在2011年开始I期临床试验的药物。SB9200顷背后慢性阻塞性肺病药物研究计划中，其他病毒感染和癌症。

bjjww

great news!

StephenW

bjjww 发表于 2011-5-7 10:28
great news!

Interesting, REP 9AC is a phosphorothiate oligonucleotides, and sb9200 is nucleic-acid-based therapeutics, like RNAi and antisense oligonucleotides. But REP 9AC has no antisense activities.